Publication | Closed Access

Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer

OncologyEarly ResponseNivolumab TreatmentCell Lung CancerMedicinePathologyImmune Checkpoint InhibitorCancer TreatmentMolecular DiagnosticsRadiation OncologyLung Cancer